<?xml version='1.0' encoding='utf-8'?>
<document id="16128905"><sentence text="Assessment of CYP1A2 activity in clinical practice: why, how, and when?" /><sentence text="The cytochrome P450 enzyme CYP1A2 mediates the rate-limiting step in the metabolism of many drugs including theophylline, clozapine, and tacrine as well as in the bioactivation of procarcinogens"><entity charOffset="108-120" id="DDI-PubMed.16128905.s2.e0" text="theophylline" /><entity charOffset="122-131" id="DDI-PubMed.16128905.s2.e1" text="clozapine" /><entity charOffset="137-144" id="DDI-PubMed.16128905.s2.e2" text="tacrine" /><pair ddi="false" e1="DDI-PubMed.16128905.s2.e0" e2="DDI-PubMed.16128905.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16128905.s2.e0" e2="DDI-PubMed.16128905.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16128905.s2.e0" e2="DDI-PubMed.16128905.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16128905.s2.e1" e2="DDI-PubMed.16128905.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16128905.s2.e1" e2="DDI-PubMed.16128905.s2.e2" /></sentence><sentence text=" CYP1A2 activity shows both pronounced intra- and interindividual variability, which is, among other factors, related to smoking causing enzyme induction, to drug intake and to dietary factors which may result in induction or inhibition" /><sentence text=" In contrast to these exogenous factors, genetic influences on enzyme activity seem to be less pronounced" /><sentence text=" Therefore, phenotyping of CYP1A2, i" /><sentence text="e" /><sentence text=" the determination of the actual activity of the enzyme in vivo, represents a useful approach both for scientific and clinical applications" /><sentence text=" CYP1A2 is almost exclusively expressed in the liver" /><sentence text=" Since liver tissue cannot be obtained for direct phenotyping, a probe drug which is metabolized by CYP1A2 has to be given" /><sentence text=" Proposed probe drugs include caffeine, theophylline, and melatonin"><entity charOffset="30-38" id="DDI-PubMed.16128905.s10.e0" text="caffeine" /><entity charOffset="40-52" id="DDI-PubMed.16128905.s10.e1" text="theophylline" /><entity charOffset="58-67" id="DDI-PubMed.16128905.s10.e2" text="melatonin" /><pair ddi="false" e1="DDI-PubMed.16128905.s10.e0" e2="DDI-PubMed.16128905.s10.e0" /><pair ddi="false" e1="DDI-PubMed.16128905.s10.e0" e2="DDI-PubMed.16128905.s10.e1" /><pair ddi="false" e1="DDI-PubMed.16128905.s10.e0" e2="DDI-PubMed.16128905.s10.e2" /><pair ddi="false" e1="DDI-PubMed.16128905.s10.e1" e2="DDI-PubMed.16128905.s10.e1" /><pair ddi="false" e1="DDI-PubMed.16128905.s10.e1" e2="DDI-PubMed.16128905.s10.e2" /></sentence><sentence text=" Caffeine is most often used because of the predominating role of CYP1A2 in its overall metabolism and the excellent tolerability"><entity charOffset="1-9" id="DDI-PubMed.16128905.s11.e0" text="Caffeine" /></sentence><sentence text=" Various urinary, plasma, saliva, and breath based CYP1A2 caffeine metrics have been applied" /><sentence text=" While caffeine clearance is considered as the gold standard, the salivary or plasma ratio of paraxanthine to caffeine in a sample taken approximately 6 hr after a defined dose of caffeine is a more convenient, less expensive but also fully validated CYP1A2 phenotyping metric"><entity charOffset="7-15" id="DDI-PubMed.16128905.s13.e0" text="caffeine" /><entity charOffset="47-51" id="DDI-PubMed.16128905.s13.e1" text="gold" /><entity charOffset="94-106" id="DDI-PubMed.16128905.s13.e2" text="paraxanthine" /><entity charOffset="110-118" id="DDI-PubMed.16128905.s13.e3" text="caffeine" /><entity charOffset="180-188" id="DDI-PubMed.16128905.s13.e4" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e0" e2="DDI-PubMed.16128905.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e0" e2="DDI-PubMed.16128905.s13.e1" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e0" e2="DDI-PubMed.16128905.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e0" e2="DDI-PubMed.16128905.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e0" e2="DDI-PubMed.16128905.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e1" e2="DDI-PubMed.16128905.s13.e1" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e1" e2="DDI-PubMed.16128905.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e1" e2="DDI-PubMed.16128905.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e1" e2="DDI-PubMed.16128905.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e2" e2="DDI-PubMed.16128905.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e2" e2="DDI-PubMed.16128905.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e2" e2="DDI-PubMed.16128905.s13.e4" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e3" e2="DDI-PubMed.16128905.s13.e3" /><pair ddi="false" e1="DDI-PubMed.16128905.s13.e3" e2="DDI-PubMed.16128905.s13.e4" /></sentence><sentence text=" CYP1A2 phenotyping is applied frequently in epidemiologic and drug-drug interaction studies, but its clinical use and usefulness remains to be established" /><sentence text="" /></document>